Navigation Links
Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2007 Financial Results
Date:11/12/2007

milestones and reimbursements earned through the company's Wyeth

collaboration

-- Total operating expenses - $55 million to $60 million

-- Operating cash requirements - $28 million to $32 million

Conference Call Details

Trubion will host a conference call and webcast to discuss its third quarter 2007 financial results. The call will be held today at 2 p.m. Pacific Time; 5 p.m. Eastern Time. The live event will be available from Trubion's Web site at http://investors.trubion.com/events.cfm, or by calling 1-888-208-1386 or 913-981-5593. A replay of the discussion will be available beginning later today from Trubion's Web site or by calling 1-888-203-1112 or 1-719-457-0820, and entering 4262106. The webcast replay will be available in the events section of Trubion's Web site.

About Trubion

Trubion is a biopharmaceutical company creating a pipeline of product candidates to treat autoimmune disease and cancer. The company's product candidates are novel proteins known as single-chain polypeptides and are designed using its SMIP custom drug assembly technology. In less than 24 months, the company designed, developed and submitted to the FDA an Investigational New Drug (IND) application for its lead product candidate, TRU-015, which has completed a Phase IIb clinical trial for the treatment of rheumatoid arthritis. In December 2005, the company entered into a collaboration agreement with Wyeth for the development and worldwide commercialization of certain therapeutics, including TRU-015. In addition, Trubion's TRU-016 program targets CD37, an antigen present on B cells, for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia. The company filed an IND for TRU-016 in the fourth quarter of 2007. Trubion currently retains all development and commercialization rights for the TRU-016 program. For additional information visit

SOURCE Trubion Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Trubion Pharmaceuticals to Present at Upcoming Investor Conferences
2. Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
11. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... PALO ALTO, Calif. , April 17, ... company, has received a SBIR grant from ... of the National Institutes of Health (NIH). ... ongoing research efforts in the development of ... complete genomes using specially fabricated substrates. Centrillion ...
(Date:4/17/2015)... 2015 Reed Technology and Information ... data management, preparation, and submission to the U.S. Food ... a new Lot Distribution Report (LDR) service for manufacturers ... compliant with the FDA’s new rule on electronic submission ... monitor the volume and timing of particular biologics introduced ...
(Date:4/17/2015)... 17, 2015 CIO Review ( http://www.cioreview.com ... 20 Most Promising Pharma and Life Science Technology Solution ... global compliance software platform for life sciences companies. ... a panel of experts and members of CIO Review’s ... MediSpend Platform has been on our radar for some ...
(Date:4/17/2015)... April 17, 2015 /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: ... company that develops and commercializes proprietary technologies and ... that it has received approval from the TSX ... outstanding common share purchase warrants ("the Warrants") of ... the Company,s May 2013 private placement financing. ...
Breaking Biology Technology:Reed Tech Announces FDA Lot Distribution Report (LDR) Service for Manufacturers of Biologic Products 2Reed Tech Announces FDA Lot Distribution Report (LDR) Service for Manufacturers of Biologic Products 3MMIS Chosen by CIO Review as Top 20 Most Promising Pharma and Life Science Technology Solution Providers 2015 2SQI Diagnostics to Extend Warrant Expiry 2SQI Diagnostics to Extend Warrant Expiry 3
... SyntheMed, Inc. (OTC,Bulletin Board: SYMD), a biomaterials ... drug delivery products and other,surgical implants, announced today ... 2008 MedTech conference being held in Washington, D.C. ... CEO of SyntheMed, is scheduled,to present on Wednesday, ...
... Keck Graduate Institute,(KGI) today announced that it will ... the latest developments in mammalian cell culture,from November ... explosive growth over the,last 25 years," said Matt ... and director of the Amgen Bioprocessing Center at ...
... results of implant operations., SAN CLEMENTE, Calif., ... to orthopedic surgeons being able to immediately gauge ... LifeModeler, Inc.,The company, a leading global provider of ... $400,000 of software and,services to InMotion Musculoskeletal Institute ...
Cached Biology Technology:SyntheMed To Present at the AdvaMed 2008 MedTech Conference 2KGI Offers Mammalian Cell Culture Program for Biotech Industry Professionals 2LifeModeler, Inc. Provides $400,000 Grant to InMotion Musculoskeletal Institute 2
(Date:4/17/2015)... , April 17, 2015 ... security concerns, and technological advancement to drive biometric ... until 2020   According to ... Arabia Biometric Systems Market Forecast &  Opportunities, 2020 ", biometric systems market ... projected to register growth at CAGR of over ...
(Date:4/14/2015)... NEW YORK , April 14, 2015 /PRNewswire/ ... Fast IDentity Online (FIDO ® ) Alliance tm ... standards-based specifications. FIDO members commit to share technology ... authentication methods that are interoperable, more secure and ... specifications enable biometric identity verification that protects sensitive ...
(Date:4/14/2015)... , April 14, 2015 NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... nominated for the 2015 New York Design Awards under ... Design100, New York City Design Awards are part of ... on over 2,500 ratings from the marketplace, industry and ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3
... I'd like to see how they calculated that, and their standard ... yet! Still, if it's a real trend, it could be alarming. ... change its pH, I guess! , A report issued by ... world's oceans. "If CO2 from human activities continues to rise, the ...
... from a study on a promising new vaccine against ... cervical pre-cancers and non-invasive cervical cancer, according to a ... Research's 4th Annual Frontiers in Cancer Prevention Research meeting ... phase III study, originally published in early October, confirmed ...
... Science University researchers have identified some of the key ... by multiple sclerosis (MS), complications of premature birth, and ... about why the nervous system fails to repair itself ... brain damage could be reversed. The research is published ...
Cached Biology News:Oceans turning to acid from rise in CO2 2Updated data on novel HPV vaccine confirms efficacy in large population 2Molecular Partners Required For Appropriate Neuronal Gene Repression 2Molecular Partners Required For Appropriate Neuronal Gene Repression 3Molecular Partners Required For Appropriate Neuronal Gene Repression 4
Mouse monoclonal [164-12-2] to Ampicillin ( Abpromise for all tested applications)....
Flotillin-2 (ESA) Purified Anti-Mouse, Anti-Rat, Anti-Human, Anti-Dog, Anti-Chicken clone 29, Isotype Mouse IgG 1 , 150 µg Consult technical datasheet for details....
... Rabbit polyclonal to Kv4.2 Immunogen ... KLH, corresponding to amino acids 23-43 of ... Cross-reacts with Rat.Expected to cross-react with Human ... with immunogen), Rabbit (100% identity with immunogen) ...
Human Presenilin-2 NTF Affinity Purified Polyclonal Ab...
Biology Products: